Sohilla Lotfy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sohilla Lotfy has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Meinhardt
Great Ormond Street Hospital 4 Immunology Department London
1 shared publication - Arnold Awuah
Great Ormond Street Hospital 4 Immunology Department London
1 shared publication - Daisy Shillingford
SIHMDS-Haematology, Great Ormond Street Hospital for Children NHS Foundation Trust 5 , London
1 shared publication - David Goldblatt
Great Ormond Street Institute of Child Health, University College London
1 shared publication - Elizabeth Rivers
Great Ormond Street Hospital 4 Immunology Department London
1 shared publication - Emma Gravett
SIHMDS-Haematology, Great Ormond Street Hospital for Children NHS Foundation Trust 5 , London
1 shared publication
Latest Publications
- Open Access
- 6 February 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (2)
Beyond survival: Multisystem long-term outcomes following HSCT in chronic granulomatous disease
Data on late complications after hematopoietic stem cell transplantation (HSCT) in children with chronic granulomatous disease (CGD) are limited. We retrospectively analyzed 42 pediatric CGD patients who survived >2 years post-HSCT (1994–2020) at Great Ormond Street Hospital. X-linked CGD accounted for 69%. Pre-HSCT comorbidities included lung disease (48%), colitis/fistulizing disease (45%), and liver abscesses (19%). Median HSCT age was 6 years. 10-year overall survival was 95.2%, and event-free survival (events: death, second intervention) was 81%. 13 (33%) cases developed autoimmunity (AI); eight had relapsing or late-onset (>2 years) AI. Organ-specific late effects included lung abnormalities (n = 7), liver dysfunction (n = 7), renal disease (n = 3), and recurrent/new-onset colitis (n = 3). Endocrine sequelae comprised obesity (n = 15), gonadal dysfunction (n = 9), and short stature (n = 7). Skeletal (n = 6), neurological (n = 6), psychological (n = 19), visual (n = 5), and hearing impairments (n = 4) were noted. Late malignancy was reported in two cases. HSCT offers excellent long-term survival in CGD, but significant late effects underscore the need for extended multidisciplinary follow-up.
- 6 February 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (2)
Open AccessBeyond survival: Multisystem long-term outcomes following HSCT in chronic granulomatous disease
Data on late complications after hematopoietic stem cell transplantation (HSCT) in children with chronic granulomatous disease (CGD) are limited. We retrospectively analyzed 42 pediatric CGD patients who survived >2 years post-HSCT (1994–2020) at Great Ormond Street Hospital. X-linked CGD accounted for 69%. Pre-HSCT comorbidities included lung disease (48%), colitis/fistulizing disease (45%), and liver abscesses (19%). Median HSCT age was 6 years. 10-year overall survival was 95.2%, and event-free survival (events: death, second intervention) was 81%. 13 (33%) cases developed autoimmunity (AI); eight had relapsing or late-onset (>2 years) AI. Organ-specific late effects included lung abnormalities (n = 7), liver dysfunction (n = 7), renal disease (n = 3), and recurrent/new-onset colitis (n = 3). Endocrine sequelae comprised obesity (n = 15), gonadal dysfunction (n = 9), and short stature (n = 7). Skeletal (n = 6), neurological (n = 6), psychological (n = 19), visual (n = 5), and hearing impairments (n = 4) were noted. Late malignancy was reported in two cases. HSCT offers excellent long-term survival in CGD, but significant late effects underscore the need for extended multidisciplinary follow-up.